- Home
- GILD vs COP Comparison
GILD vs COP Comparison
Compare GILD & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | COP |
|---|---|---|
| Founded | 1987 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Integrated oil Companies |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 136.5B |
| IPO Year | 2001 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GILD | COP |
|---|---|---|
| Price | $128.48 | $121.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 23 |
| Target Price | ★ $148.39 | $123.65 |
| AVG Volume (30 Days) | 4.4M | ★ 8.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | 2.52% | ★ 2.76% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | 6.35 |
| Revenue | $24,689,000,000.00 | ★ $58,944,000,000.00 |
| Revenue This Year | $4.68 | $6.88 |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $19.22 | ★ $19.06 |
| Revenue Growth | ★ 9.98 | 7.67 |
| 52 Week Low | $95.30 | $84.28 |
| 52 Week High | $157.29 | $135.87 |
Technical Indicators
Market Signals| Indicator | GILD | COP |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 48.65 |
| Support Level | $116.55 | $111.08 |
| Resistance Level | $142.33 | $122.50 |
| Average True Range (ATR) | 2.99 | 3.37 |
| MACD | -0.89 | -0.53 |
| Stochastic Oscillator | 1.09 | 59.30 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.